Hypoparathyroidism Market to Eyewitness Robust Expansion Growing at a 17.7% CAGR During the Study Period [2018-2030], Predicts DelveInsight
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: PR Newswire
LAS VEGAS, June 23, 2021 /PRNewswire/ -- DelveInsight's "Hypoparathyroidism Market" report provides a thorough comprehension of the Hypoparathyroidism historical and forecasted epidemiology and the Hypoparathyroidism market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Hypoparathyroidism market report also proffers an analysis of the current Hypoparathyroidism treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. Some of the necessary takeaways from the Hypoparathyroidism Market Research Report Several key pharmaceutical companies such as Takeda, Ascendis Pharma, EnteraBio, Bridgebio, Calcilytix Therapeutics, and others are developing novel products to improve the Hypoparathyroidism treatment outlook. Natpara (parathyroid hormone/rhPTH [1-84]) is the only approved drug for the Hypoparathyroidism treatment approved in the US and Europe. Ascendis Pharma's TransCon PTH showed strong data i
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Pharma A/S (NASDAQ: ASND) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $173.00 price target on the stock.MarketBeat
- Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr. [Yahoo! Finance]Yahoo! Finance
- Nacuity Pharmaceuticals Expands Board of Directors with Appointment of Dr. Emmett Cunningham, Jr.GlobeNewswire
- Advancements and Opportunities in the Achondroplasia Market: A Comprehensive Analysis and Forecast to 2032 [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $165.00 to $167.00. They now have an "overweight" rating on the stock.MarketBeat
ASND
Earnings
- 2/7/24 - Beat
ASND
Sec Filings
- 4/10/24 - Form 6-K
- 3/27/24 - Form 6-K
- 3/14/24 - Form 6-K
- ASND's page on the SEC website